CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...
Liquid biopsy is emerging as a less invasive method for cancer detection and monitoring ... and elder care. Breakthroughs in CRISPR, gene therapy, and regenerative medicine promise new frontiers in ...
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs and CD8 + T cells
This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...
even after the cancer has become resistant to drugs. The study, published today as a Reviewed Preprint in eLife, is described by the editors as a fundamental insight into overcoming treatment ...
data (`targeted`) as well as the discovery of important genes from knock-out or activation CRISPR-Cas9 screens using CRISPR pooled DNA (`screening`).
CRISPR base editing screens have also been used by researchers to map the genetic landscape of drug resistance in cancer. Coelho et al ... they become harder to scale, necessitating screening ...
State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China ...
Getting regular checkups and colon cancer screening is the best way to prevent colorectal cancer. The US Preventive Services Task Force and the American Cancer Society both recommend that people ...
Although these drugs are better tolerated than chemotherapy, they still have side effects that diminish quality of life and can leave people at risk for cancer recurrence and treatment resistance.
In conclusion, PROX1+ cells are irradiation-resistant tumor stem/progenitor cells capable of self-renewal and differentiation. DDR inhibitors could represent a strategy to target the ...
Corresponding Author: Leif W. Ellisen, MGH Cancer Center, CPZN-4204, 185 Cambridge Street, Boston, MA 02114. E-mail: [email protected] Clin Cancer Res 2025;XX:XX–XX R.O. Abelman, B. Wu, and H. Barnes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results